Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Although in vitro observations suggest that cross-presentation of antigens is mediated primarily by CD8alpha+ dendritic cells, in vivo analysis has been hampered by the lack of systems that selectively eliminate this cell lineage. We show that deletion of the transcription factor Batf3 ablated development of CD8alpha+ dendritic cells, allowing us to examine their role in immunity in vivo. Dendritic cells from Batf3-/- mice were defective in cross-presentation, and Batf3-/- mice lacked virus-specific CD8+ T cell responses to West Nile virus. Importantly, rejection of highly immunogenic syngeneic tumors was impaired in Batf3-/- mice. These results suggest an important role for CD8alpha+ dendritic cells and cross-presentation in responses to viruses and in tumor rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“appears essential for T cell-driven antitumor immunity (Hildner et al., 2008)”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
In the citing paper
“Both DC1s and DC2s expressed the DC markers Batf3, Flt3, H2-Dmb2 and Zbtb46 (Meredith et al., 2012; Hildner et al., 2008;); DC1 expressed Fscn1 and Ly 75 (DEC-205) whereas DC2s expressed CD209a (DC- SIGN), Mgl2 (CD301b) and Cd24a (Figure 2B and Figure S2B).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citationJung, S., Unutmaz, D., Wong, P., Sano, G.-I., De los Santos, K., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00365-5 · Cited by 1,773
Barnden, M. J., Allison, J., Heath, W. R., & Carbone, F. R. (1998) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1998.00709.x · Cited by 1,489
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.-W., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,455
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,328
Steady-state and inflammatory dendritic-cell development
Shortman, K., & Naik, S. H. (2007) · Nature Reviews Immunology · doi:10.1038/nri1996 · Cited by 1,190
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Bevan, M. J. (1976) · The Journal of experimental medicine · doi:10.1084/jem.143.5.1283 · Cited by 956
Toll-like receptor 3 promotes cross-priming to virus-infected cells
Schulz, O., Diebold, S. S., Chen, M., Näslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y.-T., Flavell, R. A., Liljeström, P., & Reis e Sousa, C. (2005) · Nature · doi:10.1038/nature03326 · Cited by 921
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
Cited by
Items 901–1,000 of 1,008
Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment
Lucarini, V., Melaiu, O., Tempora, P., D’Amico, S., Locatelli, F., & Fruci, D. (2021) · Cancers · doi:10.3390/cancers13030433 · Cited by 50
“The crucial role of CD103+ cDC1s was further demonstrated in Batf3−/− mice lacking CD103+ cDC1s, which fail to reject tumors and do not respond to immune checkpoint inhibition [28,29].”
BackgroundRationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
Smith, K. E., Deronic, A., Hägerbrand, K., Norlén, P., & Ellmark, P. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1934446 · Cited by 42
“Other combinations under assessment include anti-CTLA-4 and anti-PD-1, VEGF inhibitors, anti-CSF-1R, Flt3 ligand, cancer vaccines, and radiotherapy [92].”
BackgroundInfluentialTumor lysate-loaded biodegradable microparticles as cancer vaccines
Joshi, V. B., Geary, S. M., Gross, B., Wongrakpanich, A., Norian, L. A., & Salem, A. K. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2014.851606 · Cited by 39
“Mature DCs that efficiently process and present TAAs are critical for inducing systemic CTL responses with potent anti-tumor activity [35-37].”
CD8α+ DC are not the sole subset cross‐presenting cell‐associated tumor antigens from a solid tumor
McDonnell, A. M., Prosser, A., van Bruggen, I., Robinson, B. W. S., & Currie, A. J. (2010) · European Journal of Immunology · doi:10.1002/eji.200940153 · Cited by 48
Self MHC class I-licensed NK cells enhance adaptive CD8 T-cell viral immunity.
Stadnisky, M. D., Xie, X., Coats, E., Bullock, T. N. J., & Brown, M. G. (2011) · Blood · doi:10.1182/blood-2010-12-324632 · Cited by 35
“This finding exemplifies the essential role of CD8α+ cDCs in priming CD8 T cell immunity to viruses.(39) Hence, a reduction in cDC numbers, and especially the CD8α+”
BackgroundOlvera‐Gómez, I., Hamilton, S. E., Xiao, Z., Guimarães, C. P., Ploegh, H. L., Hogquist, K. A., Wang, L., & Jameson, S. C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105771109 · Cited by 38
“The CT adjuvant effect was lost in Batf3mice, animals that lack both CD8α and dermal CD103+ve DCs (28, 29).”
BackgroundMethodInfluentialChen, X., Fosco, D., Kline, D. E., & Kline, J. P. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1278332 · Cited by 41
Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector
Liu, Q., Yang, Y., Tan, X., Tao, Z., Adah, D., Yu, S., Lu, J., Zhao, S., Qin, L., Qin, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15806 · Cited by 42
“Except the polarization of Th1 responses [45], maturation of DCs, in particular of the CD8α+ DCs [46], is also positive to CTL-mediated anti-tumor immunity [47, 48].”
BackgroundInfluentialRuckwardt, T. J., Morabito, K. M., Bar‐Haim, E., Nair, D., & Graham, B. S. (2017) · Mucosal Immunology · doi:10.1038/mi.2017.28 · Cited by 43
“Batf3−/− mice lack cDC1, and have been shown to exhibit reduced CD8+ T cell responses to multiple pathogens, confirming the importance of this lineage to the development of CD8+ T cell responses (10, 26, 27).”
Desai, P., Tahiliani, V., Abboud, G., Stanfield, J., & Salek‐Ardakani, S. (2018) · Journal of Virology · doi:10.1128/jvi.00495-18 · Cited by 38
Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control
Botelho, N. K., Tschumi, B., Hubbell, J. A., Swartz, M. A., Donda, A., & Romero, P. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00294 · Cited by 41
Type 1 conventional dendritic cell fate and function are controlled by DC-SCRIPT
Zhang, S., Coughlan, H. D., Ashayeripanah, M., Seizova, S., Kueh, A. J., Brown, D. V., Cao, W. H. J., Jacquelot, N., D’Amico, A., Lew, A. M., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf4432 · Cited by 43
“In keeping with this hypothesis, DC-SCRIPT–bound chromatin regions in cDC1s greatly outnumber those in cDC2s, and these regions are often co-occupied with IRF8 and BATF3 in cDC1s, two transcriptional factors essential for their differentiation (19, 42).”
BackgroundStromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment
Papadas, A., Deb, G., Cicala, A., Officer, A., Hope, C. L., Pagenkopf, A. C., Flietner, E. D., Morrow, Z. T., Emmerich, P. B., Wiesner, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111201 · Cited by 49
Teijeira, Á., Garasa, S., Luri‐Rey, C., de Andrea, C., Gato, M., Molina, C., Kaisho, T., Cirella, A., Azpilikueta, A., Wculek, S. K., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1046 · Cited by 41
Toubai, T., Sun, Y., Luker, G. D., Liu, J., Luker, K. E., Tawara, I., Evers, R., Liu, C., Mathewson, N. D., Malter, C., et al. (2013) · Blood · doi:10.1182/blood-2012-05-432872 · Cited by 41
Herbin, O., Bonito, A. J., Jeong, S., Weinstein, E. G., Rahman, A. H., Xiong, H., Mérad, M., & Alexandropoulos, K. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.08.002 · Cited by 34
Evans, H. M., Simpson, A., Shen, S., Stromberg, A. J., Pickett, C. L., & Garvy, B. A. (2017) · Infection and Immunity · doi:10.1128/iai.00396-17 · Cited by 40
Sato, K., Uto, T., Fukaya, T., & Takagi, H. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_60 · Cited by 41
“…synthesized proteins, DCs have the capacity to deliver exogenous Ags to the MHC I-dependent pathway, a phenomenon known as cross-presentation, that underlies the generation of cytotoxic T lymphocyte (CTL) immunity (Dudziak et al. 2007; Villadangos and Schnorrer 2007; Hildner et al 2008).”
Clark, S. E., Schmidt, R. L., McDermott, D. S., & Lenz, L. L. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.106 · Cited by 43
“The transcription factor Batf3 promotes development of the CD8α+ DC population (Hildner et al., 2008); thus, we asked how loss of Batf3 expression affects the responsiveness of CD11c+ splenocytes to L1S+LPS stimulation.”
BackgroundMosaheb, M., Dobrikova, E. Y., Brown, M. C., Yang, Y., Cable, J. M., Okada, H., Nair, S. K., Bigner, D. D., Ashley, D. M., & Gromeier, M. (2020) · Nature Communications · doi:10.1038/s41467-019-13939-z · Cited by 37
Notch-Regulated Dendritic Cells Restrain Inflammation-Associated Colorectal Carcinogenesis
Wang, L., Yu, S., Chan, E. R., Chen, K.-Y., Liu, C., Che, D., Awadallah, A., Myers, J., Askew, D., Huang, A. Y.-C., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0428 · Cited by 45
Zimmerman, D. H., Taylor, P., Bendele, A. M., Carambula, R. E., Duzant, Y., Lowe, V., O’Neill, S. P., Talor, E., & Rosenthal, K. S. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2009.12.016 · Cited by 40
“subset of CD4 T cells, were resistant to CIA induction of RA [21,22] implicating Th17 T cells in the induction/maintenance of the immuno-”
BackgroundUmbilical artery acid-base status in the preterm infant.
Ramin, S. M., Gilstrap, L. C., Leveno, K. J., Burris, J., & Little, “. B. B. (1989) · PubMed · Cited by 43
Joseph, E. L. M., Kirilovsky, A., Lecoester, B., Sissy, C. E., Boullerot, L., Rangan, L., Marguier, A., Tochet, F., Dosset, M., Boustani, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002256 · Cited by 47
Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity
Provine, N. M., & Klenerman, P. (2022) · European Journal of Immunology · doi:10.1002/eji.202250022 · Cited by 41
Transcriptional regulation of dendritic cell development and function
Zhang, S., Audiger, C., Chopin, M., & Nutt, S. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1182553 · Cited by 54
“cDC1 are not only important for the activation of naïve CD8 T cells (78–80) but also for the re-activation of memory CD8 T cells which confer a faster and higher control of secondary infection, as for example in the case of Listeria monocytogenes (53).”
BackgroundInfluentialDong, L., Cao, Z. W., Chen, M., Liu, Y., Ma, X., Lu, Y., Zhang, Y., Feng, K., Zhang, Y., Meng, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51495-3 · Cited by 37
miR-22 Controls Irf8 mRNA Abundance and Murine Dendritic Cell Development
Li, H. S., Greeley, N. R., Sugimoto, N., Liu, Y.-J., & Watowich, S. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052341 · Cited by 38
“Among more than 2000 potential target genes (not shown), we selected Irf8 and Batf3 for further study, as these two genes encode transcription factors critical for DC development and function [35–43].”
BackgroundImmune-Suppressing Cellular Elements of the Tumor Microenvironment
Fearon, D. T. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034359 · Cited by 41
“F or p er so na l u se o nl y. IFN: interferon IRF: interferon regulatory factor TBK1: Tank binding kinase 1 factors (Hashimoto et al. 2011, Hildner et al. 2008) and CD8+/CD03+ DCs based on their expression of these membrane receptors.”
BackgroundSoleto, I., Fischer, U., Tafalla, C., & Granja, A. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00059 · Cited by 38
“Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.”
BackgroundInfluentialSalvermoser, J., van Blijswijk, J., Papaioannou, N. E., Rambichler, S., Pasztoi, M., Pakalniškytė, D., Rogers, N. C., Keppler, S. J., Straub, T., Reis e Sousa, C., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00699 · Cited by 36
“In this context, it is noteworthy that Clec9aCre/CreRosaDTA mice develop signs of systemic myeloproliferation, which is typical of mice lacking both cDC1 and cDC2 but has not been reported in mice lacking only the cDC1 subset (82, 83).”
BackgroundAtif, S. M., Gibbings, S. L., Redente, E. F., Camp, F. A., Torres, R. M., Kedl, R. M., Henson, P. M., & Jakubzick, C. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0159oc · Cited by 41
Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy
Amon, L., Hatscher, L., Heger, L., Dudziak, D., & Lehmann, C. H. K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070663 · Cited by 41
Chromatin Landscape Underpinning Human Dendritic Cell Heterogeneity
Leylek, R. A., Alcántara‐Hernández, M., Granja, J. M., Chavez, M., Perez, K., Diaz, O. R., Li, R., Satpathy, A. T., Chang, H. Y., & Idoyaga, J. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108180 · Cited by 45
“Finally, we found that the cDC1 TF BATF3 (Hildner et al., 2008) appeared more active in human monocytes than cDC1, which may be due to similarities between the binding motifs of BATF3 and other TFs of the AP-1 family (Friedman, 2007).”
Russler-Germain, E. V., Yi, J., Young, S., Nutsch, K., Wong, H. S., Ai, T. L., Chai, J. N., Durai, V., Kaplan, D. H., Germain, R. N., et al. (2021) · eLife · doi:10.7554/elife.54792 · Cited by 38
Defining Immunogenic and Radioimmunogenic Tumors
Medler, T. R., Blair, T. C., Crittenden, M. R., & Gough, M. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.667075 · Cited by 40
“Upon exposure to IFNg, chemokines CXCL9, CXCL10, and CXCL11 are produced by immune cells within the tumor, including macrophages and CD103+ DCs (159, 167).”
BackgroundInfluentialBickett, T. E., Knitz, M. W., Darragh, L. B., Bhatia, S., Court, B. V., Gadwa, J., Bhuvane, S., Piper, M., Nguyen, D., Tu, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0971 · Cited by 41
“Mice deficient in the BATF3 gene and lacking DC function (23) were obtained through Jackson labs (#013755).”
MethodHernández-García, E., Cueto, F. J., Cook, E. C. L., Redondo‐Urzainqui, A., Charro-Zanca, S., Robles‐Vera, I., Conde‐Garrosa, R., Nikolić, I., Sabio, G., Sancho, D., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00812-7 · Cited by 41
A Novel Engineered AAV-Based Neoantigen Vaccine in Combination with Radiotherapy Eradicates Tumors
Huang, K. C., Lai, C.-Y., Hung, W.-Z., Chang, H.-Y., Lin, P.-C., Chiang, S., Ke, T., Liang, J., Shiau, A., Yang, P.-C., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0318 · Cited by 39
Aleyas, A. G., Han, Y. W., George, J. A., Kim, B., Kim, K., Lee, C., & Eo, S. K. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902536 · Cited by 38
A mechanism of cooling hot tumors: Lactate attenuates inflammation in dendritic cells
Kanemaru, H., Mizukami, Y., Kaneko, A., Tagawa, H., Kimura, T., Kuriyama, H., Sawamura, S., Kajihara, I., Makino, K., Miyashita, A., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103067 · Cited by 39
Goh, W., Sudholz, H., Foroutan, M., Scheer, S., Pfefferle, A., Delconte, R. B., Meng, X., Shen, Z., Hennessey, R., Kong, I. Y., et al. (2024) · Nature Immunology · doi:10.1038/s41590-023-01718-4 · Cited by 38
“Indeed, loss of a single AP-1 member, Batf3 , is sufficient to block classical dendritic cell development in vivo 43 , whereas conditional Jun deletion in T cells resulted in a dramatic block in thymopoiesis 44 , underscoring nonredundant roles for individual AP-1 family members.”
Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma
Liu, X., Shen, H., Zhang, L., Huang, W., Zhang, S., & Zhang, B. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00601-1 · Cited by 47
Transcriptome Landscape of Cancer‐Associated Fibroblasts in Human PDAC
Tao, M., Liu, W., Chen, J., Liu, R., Zou, J., Yu, B., Wang, C., Huang, M., Chen, Q., Zhang, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202415196 · Cited by 63
Zhang, Y., Chen, G., Liu, Z., Tian, S., Zhang, J., Carey, C. D., MURPHY, K. M. M., Storkus, W. J., Falo, L. D., & You, Z. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500089 · Cited by 35
“B6/129S-Batf3 mice were obtained through B6 mice backcrossed with 129S-Batf3 mice (8) for five generations.”
BackgroundMethodDavison, A. M., & King, N. J. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002682 · Cited by 35
Smyth, L. A., Ratnasothy, K., Moreau, A., Alcock, S., Sagoo, P., Meader, L., Tanriver, Y., Buckland, M. S., Lechler, R. I., & Lombardi, G. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1200870 · Cited by 35
“These mice lack CD8 DCs, the subpopulation of DCs with the capacity to crosspresent exogenous Ag (39).”
BackgroundSoleimanpour, S., Hassannia, T., Mahdieh, M., Amini, A. A., & Rezaee, S. A. (2016) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2016.1163323 · Cited by 37
A Protective Role for the Lectin CD169/Siglec-1 against a Pathogenic Murine Retrovirus
Uchil, P. D., Pi, R., Haugh, K. A., Ladinsky, M. S., Ventura, J. D., Barrett, B. S., Santiago, M. L., Björkman, P. J., Kassiotis, G., Sewald, X., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.11.011 · Cited by 35
“XCR1 cDC1s are known for their CD8 T cell cross-priming abilities and require the transcription factor Batf3 for their development (Hildner et al., 2008).”
Enders, M., Franken, L., Philipp, M., Kessler, N., Baumgart, A., Eichler, M., Wiertz, E. J. H. J., Garbi, N., & Kurts, C. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900021 · Cited by 40
Contribution of Dendritic Cells in Protective Immunity against Respiratory Syncytial Virus Infection
Jung, H. E., Kim, T. H., & Lee, H. K. (2020) · Viruses · doi:10.3390/v12010102 · Cited by 47
“Batf3−/− mice, which lack CD103+ cDC1s [113], were used to elucidate the indispensable role of cDC1s in the development of CD8+ T cell responses to multiple pathogens.”
MethodCRISPR-Cas9 Ribonucleoprotein-Mediated Genomic Editing in Mature Primary Innate Immune Cells
Riggan, L., Hildreth, A. D., Rolot, M., Wong, Y.-Y., Satyadi, W., Sun, R., Huerta, C., & O’Sullivan, T. E. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107651 · Cited by 35
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript Previous studies have shown that the transcription factor Batf3 is essential for cDC1 development and protection against viral infection and tumor development (Hildner et al., 2008).”
BackgroundResultVitamin A and dendritic cell differentiation
Beijer, M. R., Kraal, G., & den Haan, J. M. M. (2013) · Immunology · doi:10.1111/imm.12228 · Cited by 43
Osorio, F., Lambrecht, B. N., & Janssens, S. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.04.020 · Cited by 39
Memory CD8(+) T Cells: Innate-Like Sensors and Orchestrators of Protection
Lauvau, G., Boutet, M., Williams, T. M., Chin, S. S., & Chorro, L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.001 · Cited by 35
The evolving biology of cross-presentation
Ohara, R. A., & MURPHY, K. M. M. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101711 · Cited by 39
Stress-associated erythropoiesis initiation is regulated by type 1 conventional dendritic cells
Kim, T. S., Hanak, M. F., Trampont, P. C., & Braciale, T. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81919 · Cited by 38
“SvEv background were previously generated (23) and were backcrossed”
Contribution of the immune system to the chemotherapeutic response
McDonnell, A. M., Nowak, A. K., & Lake, R. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0246-z · Cited by 37
“The capacity of DCs to take up exogenous antigen and shunt it into the class I processing pathway for presentation to CD8 T cells may be a specialized function of the CD8α subset and is likely to be a key process in tumor immunesurveillance [32, 210].”
BackgroundLi, Y., Liu, X., Duan, W., Tian, H., Zhu, G., He, H., Yao, S., Yi, S., Song, W., & Tang, H. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.04.008 · Cited by 41
“As a Batf3 intrinsic deficiency in T cells shown to cause no apparent defect in the development of any known helper T cell subset (Hildner et al., 2008;Murphy et al., 2013), our results demonstrate that CD8αDCs are required for the induction of a Th1 cell response under WD conditions.”
ResultGenealogy, Dendritic Cell Priming, and Differentiation of Tissue-Resident Memory CD8+ T Cells
Enamorado, M., Khouili, S. C., Iborra, S., & Sancho, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01751 · Cited by 39
Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy
Findlay, E. G., Currie, A. J., Zhang, A., Ovciarikova, J., Young, L., Stevens, H., McHugh, B. J., Canel, M., Gray, M., Milling, S. W. F., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1608106 · Cited by 39
ACKR4 restrains antitumor immunity by regulating CCL21
Whyte, C. E., Osman, M., Kara, E. E., Abbott, C. A., Foeng, J., McKenzie, D. R., Fenix, K. A., Harata‐Lee, Y., Foyle, K. L., Boyle, S. T., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190634 · Cited by 39
“CD103+ DCs have considerable interest as a therapeutic target due to their many effects on enhancing antitumor CD8+ T cell responses (Broz et al., 2014; Hildner et al., 2008; Spranger et al., 2015, 2017).”
BackgroundSynergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine
Mai, J., Li, Z., Xia, X., Zhang, J., Li, J., Liu, H., Shen, J., Ramirez, M., Li, F., Li, Z., et al. (2021) · Advanced Science · doi:10.1002/advs.202100166 · Cited by 36
Dendritic Cells: Versatile Players in Renal Transplantation
Lin, J., Wang, H., Liu, C., Cheng, A., Deng, Q., Zhu, H., & Chen, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654540 · Cited by 36
Splenic Priming of Virus-Specific CD8 T Cells following Influenza Virus Infection
Turner, D., Bickham, K. L., Färber, D. L., & Lefrançois, L. (2013) · Journal of Virology · doi:10.1128/jvi.03413-12 · Cited by 38
Transcriptional Reprogramming of CD11b+Esamhi Dendritic Cell Identity and Function by Loss of Runx3
Dicken, J., Mildner, A., Leshkowitz, D., Touw, I. P., Hantisteanu, S., Jung, S., & Groner, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077490 · Cited by 38
“Mice lacking the TF Id2, Irf8 or Batf3 are deficient in CD8+ DC [9-11] and loss of Irf4 TF affects CD4+ DC development [12].”
BackgroundBatf3 selectively determines acquisition of CD8+ dendritic cell phenotype and function
Chandra, J., Kuo, P., Hahn, A. M., Belz, G. T., & Frazer, I. H. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.83 · Cited by 34
“CD11cCre+ and Batf3−/− mice were purchased from Jacksons Laboratories and bred in house (13).”
BackgroundIL-6 selectively suppresses cDC1 specification via C/EBPβ
Kim, S. K., Chen, J., Jo, S., Ou, F., Ferris, S. T., Liu, T., Ohara, R. A., Anderson, D. A., Wu, R., Chen, M., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221757 · Cited by 32
Functional Diversity of Human Dendritic Cells
Klechevsky, E. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-15774-0_4 · Cited by 34
Tršan, T., Busche, A., Abram, M., Wensveen, F. M., Lemmermann, N. A. W., Arapović, M., Babić, M., Tomić, A., Golemac, M., Brinkmann, M. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310215110 · Cited by 33
“Additionally, the priming capacity of RAE-1γMCMV vector was assessed in Batf3 mice deficient for CD8α DCs, which can present antigenic peptides through direct or cross-presentation mechanisms (25, 26).”
BackgroundSultan, H., Wu, J., Kumai, T., Salazar, A. Μ., & Celis, E. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2164-6 · Cited by 35
“CD8α + DCs are critical for antigen crosspriming [16] and to test their role in peptide vaccine priming, we used BATF3-KO mice [28].”
A role for BATF3 in TH9 differentiation and T-cell-driven mucosal pathologies
Tsuda, M., Hamade, H., Thomas, L. S., Salumbides, B. C., Potdar, A. A., Wong, M. H., Nunnelee, J. S., Stamps, J. T., Neutzsky-Wulff, A. V., Barrett, R. J., et al. (2019) · Mucosal Immunology · doi:10.1038/s41385-018-0122-4 · Cited by 35
“15,19 BATF3 has been described to control the development of CD8α and CD103 dendritic cells.(20,21) In contrast to BATF, a nonredundant function of BATF3 in the development of TH cells has not been demonstrated.”
Lysén, A., Braathen, R., Gudjonsson, A., Tesfaye, D. Y., Bogen, B., & Fossum, E. (2019) · Scientific Reports · doi:10.1038/s41598-018-38080-7 · Cited by 36
Oncogenic kinase inhibition limits Batf3-dependent dendritic cell development and antitumor immunity
Medina, B. D., Liu, M., Vitiello, G. A., Seifert, A. M., Zeng, S., Bowler, T. G., Zhang, J. Q., Cavnar, M. J., Loo, J. K., Param, N. J., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20180660 · Cited by 36
“The Batf3-dependent dendritic cell (DC) lineage mediates the crosspriming of CD8+ T cells (Hildner et al., 2008).”
BackgroundThe GTPase Rab39a promotes phagosome maturation into MHC‐I antigen‐presenting compartments
Cruz, F. M., Colbert, J. D., & Rock, K. L. (2019) · The EMBO Journal · doi:10.15252/embj.2019102020 · Cited by 35
“This is because to initiate a CD8 T cell response in a naı¨ve host, DCs must acquire antigens from the tissues, migrate to secondary lymphoid tissues, and subsequently present peptides from the tissue antigens on MHC-I molecules to CD8 T cells (Jung et al , 2002; Hildner et al , 2008).”
Very early-life exposure to microbiota-induced TNF drives the maturation of neonatal pre-cDC1
Köhler, A., Delbauve, S., Smout, J., Torres, D., & Flamand, V. (2020) · Gut · doi:10.1136/gutjnl-2019-319700 · Cited by 34
Oba, T., Hoki, T., Yamauchi, T., Keler, T., Marsh, H. C., Cao, X., & Ito, F. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000347 · Cited by 33
Shadbad, M. A., Hajiasgharzadeh, K., Derakhshani, A., Silvestris, N., Baghbanzadeh, A., Racanelli, V., & Baradaran, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.623639 · Cited by 34
How Does B Cell Antigen Presentation Affect Memory CD4 T Cell Differentiation and Longevity?
Welsh, R. A., Song, N., & Sadegh‐Nasseri, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.677036 · Cited by 31
“Use of Batf3 knock-out (KO) mice, which lack CD8a DCs responsible for cross-presentation, found no impact on primary CD4 T cell responses but drastically impaired CD8 responses (12).”
BackgroundSemmrich, M., Marchand, J.-B., Fend, L., Rehn, M., Remy, C., Holmkvist, P., Silvestre, N., Svensson, C., Kleinpeter, P., Deforges, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003488 · Cited by 37
van Vloten, J. P., Matuszewska, K., Minow, M. A. A., Minott, J. A., Santry, L. A., Pereira, M., Stegelmeier, A. A., McAusland, T. M., Klafuric, E. M., Karimi, K., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004335 · Cited by 40
“We next questioned whether the interplay we observed between NK cells, cDC1s and T cells exists and influences outcomes in human ovarian cancer.”
cDC1 coordinate innate and adaptive responses in the omentum required for T cell priming and memory
Christian, D. A., Adams, T. A., Shallberg, L. A., Phan, A. T., Smith, T. E., Abraha, M., Perry, J. A., Ruthel, G. T., Clark, J. T., Pritchard, G. H., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq7432 · Cited by 37
Metabolic guidance and stress in tumors modulate antigen-presenting cells
Park, J., Wang, L., & Ho, P. (2022) · Oncogenesis · doi:10.1038/s41389-022-00438-y · Cited by 33
Chen, L. C., Taylor, J. L., Chi-Sabins, N., Lowe, D. B., Qu, Y., You, Z., & Storkus, W. J. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.42 · Cited by 35
Comparison of OX40 Ligand and CD70 in the Promotion of CD4+ T Cell Responses
Kurche, J. S., Burchill, M. A., Sanchez, P. J., Haluszczak, C., & Kedl, R. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000172 · Cited by 32
“with cross-presentation (45) and CD8 T cell activation (46).”
BackgroundHongo, D., Tang, X., Zhang, X., Engleman, E. G., & Strober, S. (2017) · Blood · doi:10.1182/blood-2016-07-723015 · Cited by 34
Noncanonical MAVS signaling restrains dendritic cell–driven antitumor immunity by inhibiting IL-12
Wu, L., Hong, X., Yang, C. X., Yang, Y., Li, W., Lu, L., Cai, M., Cao, D., Zhuang, G., & Deng, L. (2023) · Science Immunology · doi:10.1126/sciimmunol.adf4919 · Cited by 37
“BATF3-driven DCs are essential for tumor restriction in various cancer treatments ( 15 , 17 , 27 , 48 ).”
BackgroundMechanisms of inflammation modulation by different immune cells in hypertensive nephropathy
Hao, X., Liu, Y., Hailaiti, D., Gong, Y., Zhang, X.-D., Yue, B., Liu, J., Wu, X., Yang, K., Wang, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1333170 · Cited by 47
Qdaisat, S., Wummer, B. M., Stover, B. D., Zhang, D., McGuiness, J., Weidert, F. L., Chardon‐Robles, J., Grippin, A., DeVries, A., Zhao, C., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01380-1 · Cited by 49
“Studies have implicated the involvement of BATF3 expression, stimulator of interferon genes and interferon response factors in cancer immunogenicity 31–33 .”
Jiao, Z., Bedoui, S., Brady, J. L., Walter, A., Chopin, M., Carrington, E. M., Sutherland, R. M., Nutt, S. L., Zhang, Y., Ko, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091126 · Cited by 33
“IRF8, ID2 or Batf3 [1–4] and”
Review of Murine Dendritic Cells: Types, Location, and Development
Miloud, T., Hämmerling, G. J., & Garbi, N. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-421-0_2 · Cited by 37
Dendritic Cell Trafficking and Function in Rare Lung Diseases
Liu, H., Jakubzick, C., Osterburg, A. R., Nelson, R. L., Gupta, N., McCormack, F. X., & Borchers, M. T. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0051ps · Cited by 33
Epigenetic Regulation of Dendritic Cell Development and Function
Tian, Y., Meng, L., & Zhang, Y. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000280 · Cited by 33
van Dinther, D., Venegas, M. L., Veninga, H., Olesek, K., Hoogterp, L., Revet, M., Ambrosini, M., Kalay, H., Stöckl, J., van Kooyk, Y., et al. (2019) · Cancers · doi:10.3390/cancers11020183 · Cited by 34
Becker, W., Alrafas, H. R., Wilson, K. M., Miranda, K., Culpepper, C. D., Chatzistamou, I., Cai, G., Nagarkatti, M., & Nagarkatti, P. S. (2020) · iScience · doi:10.1016/j.isci.2020.101504 · Cited by 39
“However, increasedCD103 expression onDCs is also thought to play a role in cross-priming virus and tumor-specific cytotoxic T cells (Hildner et al., 2008), and the role of CD103+ CD11b+ DCs is less clear, displaying a double-edged sword phenotype wherein they can behave as CD103+DCs to secrete…”
BackgroundHao, L., Zhong, W. H., Woo, J. J., Wei, X., Ma, H., Dong, H., Guo, W., Sun, X., Yue, R., Zhao, J., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000019 · Cited by 33
“[13] Batf3-dependent cDC1 has been recognized as the major producer of IL-12 among all DC subsets and are essential in driving protective interferon gamma (IFN-γ)-secreting T helper type 1 (Th1) and CD8 T cells immunity upon infection.[11,14] Mice lacking cDC1s exhibited dramatically decreased intestinal IFN-γ levels…”
BackgroundT cell vaccinology: Exploring the known unknowns
Burchill, M. A., Tamburini, B. A. J., Pennock, N. D., White, J. T., Kurche, J. S., & Kedl, R. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.096 · Cited by 38
“Numerous lines of evidence ndicate that specific DC subsets in both mouse and human speialize in cross presenting exogenously provided antigens in the lass I pathway [50,52–58].”
BackgroundAntigen presentation events during the initiation of autoimmune diabetes in the NOD mouse
Ferris, S. T., Carrero, J. A., & Unanue, E. R. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.03.007 · Cited by 37
Parker, S., McDowall, C., Sanchez-Perez, L. A., Osorio, C., Duncker, P. C., Briley, A., Swartz, A. M., Herndon, J. E., Yu, Y.-R. A., McLendon, R. E., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn5649 · Cited by 36
“Thus, we examined the role of cDC1s in D+C-induced antitumor responses using Batf3−/− knockout (KO) mice lacking cDC1s (45).”
BackgroundMethodZiblat, A., Horton, B. L., Higgs, E. F., Hatogai, K., Martinez, A., Shapiro, J. W., Kim, D. E., Zha, Y., Sweis, R. F., & Gajewski, T. F. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114141 · Cited by 33
Metadata
- Authors
- Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., Schreiber, R. D., Murphy, T. L., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
- Corresponding author
- Murphy, Kenneth M.
- ORCID
- Venue
- Science
- Published
- 2008-11-14
- Volume
- 322
- Issue
- 5904
- Pages
- 1097-1100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2756611
- OpenAlex
- W2046505430
- Cited by
- 2,081
- References
- 29
- Citations by year
- 2026: 117 · 2025: 150 · 2024: 142 · 2023: 129 · 2022: 161 · 2021: 167 · 2020: 182 · 2019: 129 · 2018: 109 · 2017: 133 · 2016: 115 · 2015: 105 · 2014: 92 · 2013: 89 · 2012: 90
- FWCI
- 23.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- Batf3, CD8α+ dendritic cells, cross-presentation, West Nile virus, tumor rejection, dendritic cell development, transcription factors, antitumor immunity
- MeSH terms
- Animals, Antibodies, Viral, Cytotoxicity, Immunologic, Dendritic Cells, Female, Fibrosarcoma, Lymphocyte Activation, Male, Mice, Inbred C57BL, Repressor Proteins, Spleen, T-Lymphocytes, Cytotoxic, West Nile Fever, West Nile virus, CD4-Positive T-Lymphocytes, CD8 Antigens, Adoptive Transfer, Cross-Priming, Basic-Leucine Zipper Transcription Factors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.